Immuron Ltd — Regulatory Filings 2005

Aug 8, 2005

August 9th 2005

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam,

Please find herewith a copy of "Anadis Newsletter August 2005" for release and distribution to the market immediately.

On Behalf Of ANADIS LIMITED

CONOR GRAHAM Managing Director & CEO

EV-71 Moves To The Next Level Of Development After Successfully Reaching Key Project Milestone

The Anadis EV-71 project, developing a protective therapy against Enterovirus 71, has moved into the advanced stages of development following the reaching of a key project milestone. This milestone confirms the successful outcomes achieved in laboratory rabbit models, can now be achieved in our commercial scale production platform of dairy cattle.

To develop a natural and effective protective therapy against Enterovirus 71, being achieved at first attempt. and in an extremely short time frame compared to common drug development in Australia. and around the world, is a testament to the effort and commitment of the Anadis Scientific Team.

control Enterovirus $71$ – particularly in Taiwan - continues to be evident...this vear 60 severe Enterovirus infections were confirmed... Of these 60 severe cases, 5 have tragically resulted in the deaths of children, every one less than 4 years of $aee.$ "

"The necessity to

Since August 2004, during which Anadis first announced the successful development of a candidate protective

therapy against Enterovirus 71, much work has transpired. This includes the appointment of Dr David Anderson. an internationally recognised Virologist, to our Scientific Advisory Panel and Dr David DeLaney, our full time Senior Virologist, who joined our team located at Melbourne University, specifically focused on the commercialisation of the EV-71 Project. Now, not even a year later, we are preparing for commercial

scale manufacture of the patented vaccine, to be followed by manufacture of the actual preventative. The necessity to control Enterovirus 71

• particularly in Taiwan - continues to be evident: Up to mid June this year (2005) 60 severe Enterovirus infections were confirmed in Taiwan.

Of these 60 severe cases, 5 have tragically resulted in the deaths of children, every one less than 4 years

Dr David DeLaney inspecting an ampoule of EV71

of age; the latest case died on 31 May 2005. This is far higher than last year, which during the same period, only 14 severe cases were reported with no fatalities.

Although Enterovirus

71 is not well known throughout the western world, including Australia, it is a very significant and real threat, as an emerging disease state, in parts of Asia including Taiwan, Hong Kong and China.

GEO Réport

Dear Sharcholders.

Welcome to this, our second newsletter for 2005. Since our last newsletter in March of this year, we have continued to advance. as fast as possible on a minher of fronts.

Firstly, over the last lew months we have expanded the distribution and sale of Travelan, from Victoria to the rest of Australia. We are working very closely with Innovex Australia our sales and marketing partners, to obtain a presence in the largest number of

pharmacy retail outlets possible. In support of this national product launch, we have put in place a comprehensive nationwide advertising campaign covering various forms of print media. radio commercials and Billboard displays

We are concurrently pursuing registration of Travelan with overseas regulatory authorities and are already in discussions with a number of international parties. regarding sales and distribution. Our research and development programs

continue to successfully progress well, specifically with the EV-71 project now well into the vaccine scale-up stage. Our Immure Sumulador Infant Formula project is now nicely underway. with the aid of a \$1m government arant and our BloDefence work with the Department of Defence progressing well. In addition to these projects the other research and development currently being undertaken continue apace.

Our toll manufacturing arm continues to expand and provide cash support to both our research and development endeavors and our product sales efforts.

I would also like to take this opportunity to personally thank all of the Anadis staff and employees for their dedication and contribution taxthe company's growth over the last financial year.

Sincerely vours

Conor Graham MD & CEO

Travelan® website launched - with "on-line" purchase facility for international orders

The new Travelan® website, www.travelan.com.au. was launched at the end of May . On the website there is a wealth of information about the product, a Common Questions page and Real Life Stories, from people who have benefited from Travelan®. The website also has the facility for anyone internationally to purchase Travelan

for personal use. This facility is intended only for orders outside of Australia and purchases are completed in US dollars. Locally, Travelan® is available in all good chemists and pharmacies. So for more information about Travelan^®, and the chance to win an adventure holiday. please visit our new product website.

Travelan prepares to pack its bags in US anticipation...

Anadis, due to the significant numbers of travellers in the United States. It has been estimated that each vear 20 to 25 million Americans travel to E coli "high risk" areas. These mumbers do not include the even higher figures for travel to intedium risk" destinations.

The interest in Travelan internationally is not surprising. Travelan has received extensive praise by travellers, including: a 20 person delegation, from the Australian Industry Group, who travelled to India - all used Travelan and none became ill and a Team of Optometrists, who used Travelan whist working in Achai, Indonesia, also reporting no problems.

Iravelan is currently undergoing registration in Singapore and the UK EU: Travelan is also being looked at for registration in places including Pakistan. the Middle Past, Japan, Taiwan, Thailand, and findia.

ANADIS LIMITED ACREEMENT

a Capital Link Drive Campbellisch! Victoria, Australia 3091. Phone (61+3) 9358 6388 Fax (61+3) 9358 6399

At this time. Anadis believes that it has submitted all appropriate information and has the "green light' to begin marketing Travelan in the United States (upon confirmation, this will officially be announced on the ASXY Steven Skorobogaty, our General Manager - Commercial has successfully returned from an extensive trip to the US. Steven met with a number of companies that could potentially become partners for the manufacturing, distribution and marketing, of Travelan in the US. Conor Graham (CEO) and Steven plan

To enter simply share your travel adventures with Travelan*

Simply visit the Travelan website: www.travelan.com.au to enter!

Staff Member Profile Staff Member Profile

Aric Nudel

Investor Relations & Hrecten

Aric toined Anadis in 2003 as a consultant in the Investor Relations role and has been working to increase communication with existing and potential shareholders focusing on details and development of Anadis

Arie has recently been appointed to the board of Anadis

Arie has a Bachelor of Commerce and a Bachelor of Science from the University of Melbourne. Aric has a diverse

professional background and began work as a Microsoft Certified Networks Engineer Later, Arie joined a Melbourne based funds management company and worked as a Systems Analyst and Dealer In 2003, Arie began his own consultancy company, and in addition to working for Anadis Ltd, consults for a number of private companies.

At his role at Anadis. Arie has been able to acquaint himself with investor needs and expectations in Anadis Limited and the Biotechnology sector in

general, With his appointment to the board Arie is expected to better convey these ideas to help achieve improved shareholder outcomes. Arie has recently become a father for the first time to leremy fle enjoys a range of outdoor activities and has a number of computer related hobbies.

Anaidis Manufacturing Update

Contract manufacturing

efficiencies

Once again the Anadis Manufacturing Division has achieved a significant increase in goods manufactured and vales revenue. Anadis continues to build on its experience, quality, speed, cost effectiveness, and responsibility to meet its production needs.

Production is recognised as an adjunct to Anadis' core focus, and our customers recognise the many advantages of working with a Biopharmaceutical based Research & Development Company that can provide first class manufacturing and an accessible route to intellectual stimulation and discussion towards further product development

Our customers, both

Main blending room in operation.

current and prospective. recognise the many advantages of contract packaging such as: reduced staffing, training & maintenance costs, fixed unit cost with no capital investment and none of the problems of setting up new production lines.

Our continuing aim in the contract manufacturing division has been to form strategic partnerships with our cusiomers. This is to ensure that their products succeed in the market place and we can establish not only long-term manufacture atrangements, but also consultancy support in the fields of government. food and veterinary regulations.

We look forward to the continued growth and development of this key component of Anadis' business.